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Abstract
Background: Defects of the primary cilium and its anchoring structure, the basal body, cause a number of human
genetic disorders, collectively termed ciliopathies: primary ciliary dyskinesia, Bardet-Biedl syndrome, polycystic
kidney and liver disease, nephronophthisis, Alström syndrome, Meckel-Gruber syndrome and some forms of
retinal degeneration.
Alström syndrome is an extremely rare, autosomal recessive genetic disorder characterized by a group of signs
and symptoms including infantile onset dilated cardiomyopathy, blindness, hearing impairment/loss, obesity,
diabetes, hepatic and renal dysfunction.
Because adult growth hormone deficiency and Alström Syndrome share some clinical and metabolic features, we
studied the GH-IGF1 axis, using MRI techniques and dynamic tests in 3 unrelated patients with Alström syndrome.
Case presentation: The patients were hospitalized and the growth hormone stimulatory tests were made, as
well as brain MRI. Insulin provocative test revealed a severe GH deficiency in these patients, defined by a peak
response to insulin-induced hypoglycemia less than 3 ng/dl and IGF1 concentrations less than – 2SDS.
We didn't find multiple pituitary hormone deficiency and we noticed only a severe GH deficiency in all three
patients. The MRI study of the diencephalic and pituitary region was suggestive for the diagnosis of empty sella in
one patient.
One patient received Recombinant-GH replacement for one year with very good results, one underwent a gastric
sleeve with a satisfactory outcome, one patient died due to the progression of the cardiac myopathy.
Conclusion: Future studies are needed to assses if the substitution therapy with Recombinant Growth hormone
is cost-effective and without risk in such patients with Alström Syndrome and severe insulin resistance, despite
our good results in one patient. Also, careful clinical and genetic studies can contribute to a better understanding
of the evolution after different therapeutical attempt in the complex disorders such as Alström Syndrome.
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Background
Alström syndrome is a rare autosomal recessive disorder
[1], caused by mutations in a gene of unknown function
(ALMS1) [2] and it is characterized by several phenotypes
reminiscent of Biedl-Bardet syndrome, including retinal
degeneration, obesity and diabetes. ALMS1 protein local-
izes to centrosomes and to the base of cilia. In fibroblasts
with disrupted ALMS1, primary cilia and the microtubule
cytoskeleton appear to be normal, suggesting that the
ALMS phenotype results from impaired ciliary function
rather than from abnormal ciliary structure [2].
Central features of Alström syndrome include obesity,
insulin resistance, and type 2 diabetes, and therefore
investigating such patients could offer new insights into
the pathogenesis of these common conditions [2].
Primary cilia are ubiquitous cellular appendages that pro-
vide important yet not well understood sensory and sign-
aling functions. Until recently, cilia were thought to be
simple external cellular organelles, but now they are
thought to play important roles in cell signaling, in sens-
ing chemical and physical activity, in intracellular com-
munication, and as photoreceptors. The significance of
primary cilia is exemplified by the fact that defects in cilia
formation or function cause renal cystic disease, retinal
degeneration, liver fibrosis, anosmia, ataxia, cardiac
defects, and situs inversus [3,4].
Although all ciliopathies arise from defective cilia, the
range of symptoms can vary significantly [5], and only a
small subset of the possible ciliary disease symptoms may
be present in any given syndrome, because the cilia are
themselves exceedingly complex machines that perform
multiple functions simultaneously [6-9].
There is growing evidence that cilia are connected with the
cellular signaling involved in modern illnesses such as
obesity and diabetes, e.g. an increasing number of genetic
diseases being associated with defects in ciliogenesis or
ciliary function [10-20], including Alstrom and Bardet-
Biedl syndromes [2,18].
The complex links in the central nervous system between
neuronal cilary dysfunction in the brain areas such as the
hypothalamus, involved in appetite control, and obesity
may be explained by the mechanisms of ciliary maintenance
and lead to hyperphagia, a low metabolic rate, autonomic
imbalance, growth hormone (GH) deficiency and various
other problems that contribute to weight gain [21-24].
It is important to identify those at high risk of hypotha-
lamic obesity so that weight gain prevention approaches
can be offered. In those who are already obese, the princi-
pal causal mechanism should be considered as a basis for
guiding clinical management [25-27].
Also, by studying such rare disorders we could understand
the complex mechanisms of obesity and diabetes, were,
dietary habits and exercise could be sometimes accompa-
nied by genes linked to cilia and basal bodies, making
some people more susceptible to obesity than others.
Case presentation
Considering that hypothalamic ciliary neuronal dysfunc-
tion is implicated in the etiology of obesity in Alström
syndrome patients, we studied the presence of GH defi-
ciency in our patients, because we assume that an early
preventive intervention in such patients is GH replace-
ment.
We evaluated hypothalamic-pituitary-GH axis, by study-
ing the GH-IGF1 axis, using MRI techniques and dynamic
tests in 3 unrelated patients with Alstrom syndrome.
To characterize the GH-IGF1 system in Alström syn-
drome, we evaluated our 3 patients with Alström syn-
drome for hepatic, renal and thyroid function. Glycaemic
and hormone measurements such as insulin, GH, FSH,
LH, testosterone and 17-beta-oestradiol were assessed. A
significantly lower height was observed in our patients
compared to age-matched controls. Also, all patients were
clinically obese (by weight and body mass index (BMI)
standards). Only 2 patients presented with fasting hyper-
glycaemia, but all 3 were hyperinsulinaemic. TSH was
normal. Baseline FSH and LH in the 2 females (Patient 2
and Patient 3) were within the normal range, while the
male (Patient 1) had an abnormally low testosterone
value. Free IGF1, IGFBP-1 were significantly reduced and
IGFBP-2 was markedly increased in all 3 patients com-
pared to age-matched controls, which points to a growth
hormone deficiency (GHD) condition in Alstrom syn-
drome.
All 3 subjects had anthropometric and laboratory param-
eters checked at baseline. After a 12-hour overnight fast,
blood specimens were obtained for plasma glucose, trig-
lycerides, glycosylated hemoglobin (HbA1c), and serum
total, low-density lipoprotein (LDL), and high-density
lipoprotein (HDL) cholesterol. Patients who were using
insulin (patient 1 and patient 2) had their treatment
stopped the day before the test, but were closely moni-
tored for the glycemic status.
An insulin tolerance test (ITT), consisting of a bolus of
regular human insulin (0.1 U/kg body weight equivalent
to 5.22 ± 0.44 U/m2 of body surface) was performed in
each patient.Cases Journal 2009, 2:19 http://www.casesjournal.com/content/2/1/19
Page 3 of 9
(page number not for citation purposes)
At present, the insulin tolerance test is the diagnostic test
of choice for the study of GH-IGF1 axis in obese patients.
If provided adequate hypoglycemia is achieved, this test
distinguishes GH deficiency from the reduced GH secre-
tion that accompanies normal aging and obesity.
Most normal subjects respond to insulin-induced
hypoglycemia with a peak GH concentration of more than
5 ng/dl. Severe GH deficiency is defined by a peak GH
response to hypoglycemia of less than 3 ng/dl [28-30].
Patient 1
The first patient diagnosed with Alström syndrome in our
department was a 20-year-old boy, born from a non-con-
sanguineous parents. During his first year of life were
noted increased weight gain and progressive and worsen-
ing pathological ocular signs: nystagmus (at 4 months)
and photophobia (at 12 months), reduced visual acuity.
Sensorineural hearing impairment was noted at 15 years
of age and type 2 diabetes mellitus was diagnosed at 16
years of age (Figure 1). From that point, he has been on
insulin therapy, in different protocols, with 3 of 4 injec-
tions/day. The needed dose of insulin in order to obtain a
good glycemic control was more than 200 IU/day. At this
point, diabetes mellitus was considered as the result of
resistance to the action of insulin. He never developed
ketosis or diabetic keto-acidosis (DKA). Also, abnormal
liver and kidney function tests were noted, an increased
level of triglycerides with normal cholesetrol, with normal
intelligence, normal extremities, normal secondary sexual
characteristics. Systolic dysfunction of the left ventricle
was diagnosed by echocardiography (long parasternal axis
showed diffuse hypokinesia with mitral valve failure).
Using Tissue Doppler Application, longitudinal velocity
shortening and pulmonary hypertension 65–70 mmHg
were also found.
We studied the GH-IGF1 axis, using MRI techniques and
dynamic tests (insulin tolerance test). The MRI study of
the diencephalic and pituitary region was suggestive for
the diagnosis of empty sella (Figure 2). We found normal
TSH (Thyroid Stimulating Hormone), fT3 (free triio-
dothyronine), fT4 (free thyroxine), and negative results
for anti-thyroid auto-antibodies. Growth hormone stimu-
latory tests were made and insulin provocative test
revealed a severe GH deficiency in this patient, defined by
a peak response to insulin-induced hypoglycemia less
than 3 ng/dl and IGF1 concentrations less than -2SDS.
The values were: GH1 – 0,18 ng/mL, GH2 – 0,49 ng/mL
(after the stimulation with insulin 0,4 iu/kg/dose), IGF-1
– 49 ng/ml (N:116–356 ng/ml). Because of the insulin
resistance, the needed dose of insulin in order to achive
the hypoglycemia, was 4 times greater than usual.
Multiple pituitary hormone deficiency (MPHD) wasn't
found and we noticed only severe GH deficiency and an
abnormally low testosterone value. The presence of empty
sella seems to be a rare morphologic finding in Alström
syndrome though it was described in patients with Bardet-
Biedl syndrome [31].
Decreased serum levels of GH, which acts on cardiac myo-
cytes primarily through IGF-1, are associated with
impaired myocardial growth and function, which can be
improved with restoration of GH/IGF-1 homeostasis [32].
Patient 1 Figure 1
Patient 1.
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This effect of GH on cardiac tissue may explain why the
patient had multiple episodes of cardiac decompensation
due to severe cardiomyopathy and finally died at 28 years
of age.
Also, due to the severity of the cadiomyopathy, we were
reluctant to consider the Re-GH administration in this
case.
The patient was included in a study of linkage mapping
(Jackson Laboratory, Bar Harbor, Maine). Interestingly, so
far, the Alström patient doesn't have any of the known
ALMS1 mutations and he did not have any of the known
BBS mutations either. He had one heterozygous SNP in
BBS5 (BBS5_N184S het) that is not disease-causing.
Despite the fact that this case was analyzed for years with-
out the identification of a known mutation, efforts are still
made using the Asper Biotech Gene Chip, in order to iden-
tify a possible new unknown mutation(s) that may
explain the phenotypic diagnosis.
Patient 2
The second patient is a girl, 14-y-o, diagnosed with
Alström syndrome clinically and genetically (Jackson Lab-
oratory, Bar Harbor, Maine, USA). The genetic testing per-
formed at Jackson Laboratory, Bar Harbor, Maine revealed
in exon 16, in the ALMS1 gene in patient's DNA, 2 differ-
ent mutations: 10753 C > T Ter and 10780 C > T Ter.
The first sign, nystagmus, was noted at 4 months of age,
then she developed progressive retinal distrophy and
blindness by 10 years of age. Infantile obesity progressive
with age, sensorineural hearing impairment, type 2 diabe-
tes mellitus, abnormal liver function tests, reccurent uri-
nary tract infections, urinary incontinence, scoliosis,
kyphosis, acanthosis nigricans, obesity (123 kg/167 cm,
BMI = 44.1 kg/m2) but, normal intelligence, normal
extremities, normal secondary sexual characteristics were
noted during the evolution.
We studied the GH-IGF1 axis, using MRI techniques and
dynamic tests (insulin tolerance test).
We found a severe GH deficiency, defined by a peak
response to insulin-induced hypoglycemia less than 3 ng/
dL and IGF1 concentrations less than -2SDS.
The values were: GH1 – 0,18 ng/mL, GH2 – 0,17 ng/mL
(after stimulation with insulin 0,2 IU/kg/dose), IGF-1
(somatomedin c) – 67 ng/mL (116–356).
Because of the insulin resistance, the needed dose of insu-
lin in order to achive the hypoglycemia, was 2 times
greater than usual.
The MRI study of the diencephalic and pituitary region
was normal (Figure 3).
We found normal TSH (Thyroid Stimulating Hormone),
fT3 (free triiodothyronine), fT4 (free thyroxine), and neg-
ative results for anti-thyroid auto-antibodies. Multiple
pituitary hormone deficiency (MPHD) wasn't found and
we noticed only severe GH deficiency.
We used Re-GH in this patient for 12 consecutive months,
in a dose of 0,25 mg/day, with very good results: the total
body fat mass decreased after one year, most significant in
visceral trunk location as revealed by DEXA body compo-
sition, the bone density increased with 5% after 6 months
(Figure 4). Echocardiography has shown that left ventricu-
lar mass index, fractional shortening and fiber shortening
velocity improved after 12 month of low-dose therapy
(Figure 5). No lipid metabolism improvement was noted,
but a psychological well being was observed. Insulin sen-
sitivity and acanthosis nigricans improved. Glucose-to-
insulin ratio increased from 3.45 to 4.52 after one year.
Patient 3
The third patient is a 13-y-o girl with severe obesity (Fig-
ure 6) who was examined in our department after the gas-
tric sleeve was performed for her severe obesity resistant to
diet and medical treatment for years.
The past medical history revealed the presence of nystag-
mus from 4 months of age and progressive obesity during
her infancy and childhood. The patient has normal
extremities and normal inteligence, no sensorineural
hearing impairment was noted yet, nor type 2 diabetes
mellitus, and thyroid disorders. Differential diagnostics
included lysosomal storage diseases and aminoacidopa-
thies, but these disorders were excluded. Several labora-
tory tests showed normo-glycemia, mild
Patient 1 Figure 2
Patient 1. Magnetic resonance imaging – morphologic 
appearance suggesting “empty sella”.   Cases Journal 2009, 2:19 http://www.casesjournal.com/content/2/1/19
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hypertriglyceridemia, and hypercholesterolemia and nor-
mal liver transaminases and renal function tests. Mild to
moderate insulin-resistance was noted, as revealed by glu-
cose-to-insulin ratio (GIR) = 4.3 Obese patients with a
fasting GIR of 4.5 or more have insulin sensitivity, while a
GIR of less than 4.5 means insulin resistantance. Fasting
Insulinemia: 18.5 uU/mL (Normal: 2.6–24.9). We stud-
ied the GH-IGF1 axis, using MRI techniques and dynamic
tests (insulin tolerance test): GH 1- 0.32 ng/mL, GH 2-
0.24 ng/mL (when hpoglycemia was induced, glycemia <
40 mg/dl), IGF-1 162 ng/mL (Normal: 220–972).
Insulin resistance as well as growth hormone deficiency
was diagnosed in this patient; her DNA was sent to Jack-
son Laboratory, Maine, USA for the genetic testing and we
are pending for the results.
Despite the gastric sleeve and considerable weight loss
(about 45 kg in 9 months), this patient was diagnosed
with GH deficiency unrelated to obesity, and we are con-
sidering the Re-GH administration in her case.
We noticed an important clinical variability among these
patients, characteristic for the ciliopathies, given the mul-
tiple roles of cilia in development and physiology.
The first sign noticed in all these 3 affected patients was
the presence of nystagmus and light sensitivity in infancy.
Congestive heart failure resulting from dilated cardiomy-
opathy was diagnosed in patient 1 in adolescence, leading
to his death, by the age of 28. Also, the cardiomyopathy
was diagnosed in patient 2, but some improvements were
noted after the treatment with Re-GH.
As infants and toddlers all 3 patients were overweight.
Hearing impairment was diagnosed in patients 1 and 2,
and all 3 became insulin resistant as adolescents. Patient
1 and patient 2 were diagnosed with type 2 diabetes mel-
litus in the 2-nd decade of life.
Other findings observed in our Alström Syndrome
patients: acanthosis nigricans, short stature, abnormal
liver and kidney tests in patients 1 and 2, and normal
intelligence, normal extremities, normal secondary sexual
characteristics in all 3 patients, making possible the differ-
ential diagnosis with Bardet-Biedl syndrome.
Patient 1 was diagnosed with empty sella, based on the
brain MRI exam, this finding being unusual so far in
Alström Syndrome patients.
Studying the medical literature, we noticed that consider-
able variability exists in the expression of the clinical signs
of Alström Syndrome, even among siblings, and not all
people who have Alström Syndrome will experience all of
the characteristic features [27].
Patient 2 Figure 3
Patient 2. Normal MRI study of the diencephalic and pituitary region.Cases Journal 2009, 2:19 http://www.casesjournal.com/content/2/1/19
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All 3 patients in our series were diagnosed with GH defi-
ciency, based on the results of the provocative tests using
insulin, one problem of great concern being the obesity.
The somatotropic response to all provocative stimuli is
negatively correlated to BMI and the GH response in
obese subjects is sometimes as impaired as that in hypop-
ituitary patients with severe GHD [33-35]. The impair-
ment of GH secretion in obese would reflect alterations in
the neuroendocrine control of the somatotropic axis and/
or metabolic alterations such as hyperinsulinism and ele-
vation of circulating free fatty acids [36]; reduction of GH
half life in obese subjects has also been demonstrated
[37,38]. For the ITT, the classical cut off level of 3 ng/dl
can be considered appropriate based on well known evi-
dence that this level distinguishes normal subjects
(including obese) from patients with severe GHD [33,34],
in order to avoid false positive diagnosis in obese adults.
We used the ITT and the classical cut off level of 3 ng/dl
when we assessed the impairment of GH secretion in our
patients.
It is supposed that the genetic alteration leads to dysfunc-
tion of several hypothalamic centres and growth hormone
(GH) deficiency (GHD) in Alström syndrome.
In our case series, at baseline the activity of the GH-insu-
lin-like growth factor-1 (IGF-1) system was impaired with
low GH values, low total IGF-1 and in relation to the obes-
ity low levels of free IGF-1 and non-suppressed IGF-bind-
ing-protein-1 (IGFBP-1). Bone mineral density (BMD)
assesed in one patient was low. Two patients had diabetes
mellitus, and all three had a glucose-to-insulin ratio (GIR)
less than 4.5 indicating insulin resistance. One patient
subsequently completed a 12 months GH treatment trial,
and GH had beneficial effects on body composition with-
out significant adverse effects. More, the echocardiogra-
phy performed in this patient has shown that left
ventricular mass index, fractional shortening and fiber
shortening velocity improved after 12 month of low-dose
therapy. No lipid metabolism improvement was noted,
but a psychological well being was observed. Insulin sen-
sitivity and acanthosis nigricans improved. Glucose-to-
insulin ratio increased from 3.45 to 4.52 after one year.
Demonstrating GHD in an Alström syndrome patient, Tai
TS, Lin SY, Sheu WH assessed the metabolic effects of
growth hormone therapy concluding that Re-GH therapy
might have beneficial effects on body composition, liver
fat content, lipid profiles, and insulin resistance in
Alström syndrome patients, with improvement of the glu-
cose homeostasis [39].
Also, Maffei et al. found a reduction of ALS (acid labile
subunit) and the increase of IGFBP-2 as expression of
growth hormone deficiency (GHD) condition in 15
young adults with Alström syndrome [40].
Considering Recombinant-GH as treatment in to 8 pedi-
atric patients with stable chronic heart failure secondary
to dilated cardiomyopathy (DCM), McElhinney and the
other authors determined several notable cardiovascular
effects, including a trend toward improved LV ejection
fraction during the course of GH treatment and signifi-
cantly improved LV SF, SF z score, and LV end systolic
stress z score 6 months after discontinuation of GH treat-
ment (relative to baseline values) [41]. Re-GH wasn't tried
so far in Alström syndrome patients with cardiac myopa-
thy, as an alternative to the classical treatment.
Concerning the gastric sleeve, we consider that this proce-
dure should be addressed to extremely obese patients with
Alstrom syndrome, (typically with BMI greater than 40),
DEXA body composition analysis Figure 4
DEXA body composition analysis. Patient 2. Height/
Weight: 167 cm/120 kg. Sex/Etnic: Female/White. Total 
region = 1,158 g/cm2 BMD1Cases Journal 2009, 2:19 http://www.casesjournal.com/content/2/1/19
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who have reached their adult height (usually 13 or older
for girls and 15 or older for boys), and have serious
weight-related health problems, such as type 2 diabetes,
sleep apnea, heart disease, or significant functional or psy-
chosocial impairment. In addition, potential patients and
their parents should be evaluated to see how emotionally
prepared they are for the operation and the lifestyle
changes they will need to make.
Conclusion
This case series showed that adolescents and adults with
Alström syndrome have GH deficiency, and recombinant
GH therapy might have beneficial effects on body compo-
sition, and insulin resistance, with improvement of the
glucose homeostasis and cardiac function. Larger and
longer term studies on the effect of GH replacement in
Alström syndrome patients are encouraged, to assess if the
substitution therapy with Recombinant Growth hormone
is cost-effective and without risk in such patients with
Alström Syndrome and severe insulin resistance, knowing
that the state of GH deficiency seen in Alström syndrome
renders these patients exposed to a lifelong risk of meta-
bolic disturbances.
Further careful clinical and genetic studies of such patients
can contribute to a better understanding of the evolution
after different therapeutical attempts in the complex dis-
orders such as Alström Syndrome.
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